FilingSEC EDGAR8-K
BioXcel Therapeutics Completes Sale of Neuroscience Assets
· SEC accepted
StageSale Completed
Filing content
The company completed the sale of its neuroscience assets, including IGALMI and BXCL501, to Teva Pharmaceuticals for $57.5 million following court approval. It remains eligible for potential future milestone payments contingent on FDA approval and commercial performance.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…